Vicore Pharma Holding AB (STU:6Y4) Research & Development: €37.95 Mil (TTM As of Mar. 2026)


STU:6Y4 Vicore Pharma Holding AB STU:6Y4
34 GF Score
Price €1.10
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Research & Development?

Vicore Pharma Holding AB STU:6Y4 -0.36% 34 Research & Development is €37.95 Mil as of Mar. 2026. GuruFocus rates STU:6Y4 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vicore Pharma Holding AB's Research & Development for the three months ended in Mar. 2026 was €9.53 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €37.95 Mil.

Vicore Pharma Holding AB  (STU:6Y4) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vicore Pharma Holding AB Research & Development Related Terms

Vicore Pharma Holding AB Research & Development Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Research & Development Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.47 22.74 24.70 21.67 35.87

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.19 9.03 9.01 10.39 9.53
STU:6Y4
34GF Score
Vicore Pharma Holding AB STU:6Y4
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €37.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €37.95 Mil mean?
Vicore Pharma Holding AB (STU:6Y4) has a Research & Development of €37.95 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Research & Development too high?
Vicore Pharma Holding AB's current Research & Development is €37.95 Mil. Overall, Vicore Pharma Holding AB has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Research & Development compare to VRTX and REGN?
Vicore Pharma Holding AB's Research & Development of €37.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Research & Development is €37.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (STU:6Y4) has a current Research & Development of €37.95 Mil. The current Research & Development is €37.95 Mil. Vicore Pharma Holding AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vicore Pharma Holding AB (STU:6Y4), the current Research & Development is €37.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Other Exchanges VICO:Sweden
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
34GF Score

Get the complete analysis for STU:6Y4

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.10
Price